Skp2 and Chemotherapy Resistance in Breast Cancer
Author Information
Author(s): Davidovich Shirly, Ben-Izhak Ofer, Shapira Ma'anit, Futerman Boris, Hershko Dan D
Primary Institution: Rambam Medical Center and the Technion-Israel Institute of Technology
Hypothesis
The study aims to examine the role of Skp2 and p27Kip1 as predictors of clinical outcome and response to chemotherapy in locally advanced breast cancer.
Conclusion
Skp2 expression may be a useful marker for predicting response to doxorubicin-based preoperative chemotherapy and clinical outcome in patients with locally advanced breast cancer.
Supporting Evidence
- High preoperative expression of Skp2 was associated with resistance to CAF therapy in 94% of patients.
- Both Skp2 and p27Kip1 were found to be accurate prognostic markers for disease-free and overall survival.
- Patients with high Skp2 expression had significantly poorer disease-free and overall survival.
Takeaway
This study found that high levels of a protein called Skp2 can make breast cancer harder to treat with certain chemotherapy drugs.
Methodology
The expression levels of Skp2 and p27Kip1 were determined by immunohistochemistry in 40 patients with locally advanced breast cancer before and after preoperative chemotherapy.
Limitations
The study had a small sample size and focused only on specific chemotherapy regimens.
Participant Demographics
{"age":{"median":47,"range":"29 to 79"},"histology":{"ductal":"82%","lobular":"18%"},"tumor_grade":{"G1":"7%","G2":"53%","G3":"40%"},"lymph_node_status":{"positive":"60%","negative":"40%"}}
Statistical Information
P-Value
P < 0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website